Tag Archives: sanofi

A few stocks, including some of the ones below, are being classified as COVID-19 stocks because of their potential to rise even as the pandemic worsens.Apart from the obvious health effects, the current coronavirus pandemic has already depleted financial markets all over the world. As the outbreak continues to spread and the world records a lot more confirmed cases, these economic effects are also going to continue. Many companies are already recording heavy losses and many of the world’s...

Five pharmaceutical companies across the globe lead the race in producing the first approved COVID-19 vaccine. Wall Street is likewise on alert for banking on the first company to produce an efficient one.As the battle against the spread of coronavirus outbreak across the world intensifies, many companies are working to put themselves at the forefront in producing viable COVID-19 vaccine.Producing a vaccine for human testing and adoption to address the Coronavirus outbreak remains as crucial...

Dow Jones has lost over 1,880 points due to a row of factors including Saudi’s oil price slash as well as the coronavirus that is quickly spreading. More bleeding is expected.All over the world, markets have been feeling terrible effects of the coronavirus COVID-19 outbreak. In recent times, the epidemic has caused stocks to plunge considerably, with a lot of companies seriously bleeding. Projections for the coronavirus have been quite pessimistic with forecasts that things will get worse....

Moderna Inc (MRNA) stock has been skyrocketing since the company announced its mRNA COVID-19 vaccine has been successfully shipped to the National Institute of Allergy and Infectious Diseases.Moderna Inc (NASDAQ: MRNA), a biotech company that is focused on drug discovery and also in the drug development, has seen its stock market value continue rising even hours after it announced the release and shipment of its COVID-19 vaccine. The shares so far are up by 7.11% in the pre-market, where at...

French multinational company Sanofi SA stated on Monday that it will buy biotechnology company Synthorx Inc. for a combined equity value of approximately $2.5 billion. In other words, it will be $65 per share.The acquisition is expected to close in the first quarter in 2020 and the company believes it will strengthen Sanofi’s existing immuno-oncology portfolio.Paul Hudson, who is the CEO of Sanofi, said:“This acquisition fits perfectly with our strategy to build a portfolio of high-quality...